This is a study to determine if a certain drug, called telotristat ethyl (Xermelo®), can help reduce the chance of blood pressure and heart rate variations (known as carcinoid crisis) in individuals who have neuroendocrine tumors (also called carcinoid tumors). These complications can be life-threatening for patients who already have to experience challenging surgeries to remove their tumors. To determine if telotristat ethyl (Xermelo®) will help reduce these complications during surgery, researchers will give the drug to study participants before surgery.

开始日期2022-01-01

申办/合作机构

The University of Chicago

NCT04543955

/ Terminated临床2期IIT

Study of Telotristat (Xermelo) in Combination With Luetetium Lu177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors

This trial will test the hypothesis that Telotristat treatment increases the antitumor efficacy of Lutetium Lu 177 Dotatate therapy in neuroendocrine tumors (NETs).

开始日期2021-09-13

申办/合作机构

University of Kentucky

[+1]

NCT04810091

/ Active, not recruiting临床3期IIT

TELEHEART: Telotristat Ethyl in a Heart Biomarker Study

This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to other places in the body (metastatic). Telotristat ethyl and somatostatin analog therapy may help to control carcinoid syndrome and carcinoid heart disease.

开始日期2021-05-18

申办/合作机构

The University of Texas MD Anderson Cancer Center

100 项与特罗司他乙酯相关的临床结果

登录后查看更多信息

100 项与特罗司他乙酯相关的转化医学

登录后查看更多信息

100 项与特罗司他乙酯相关的专利（医药）

登录后查看更多信息

130

项与特罗司他乙酯相关的文献（医药）

2025-05-01·Advances in Therapy

Burden of Comorbidities and Concomitant Medications and Their Associated Costs in Patients with Gastroenteropancreatic or Lung Neuroendocrine Tumors: Analysis of US Administrative Data

Article

作者: Dennen, Syvart ; Ribeiro-Oliveira, Antonio ; Starr, Jason ; Chan, Jennifer A ; Liu, Yutong ; Houchard, Aude ; Naga, Sai Sriteja Boppudi ; Zhao, Yajin ; Pommie, Christelle ; Vandamme, Timon

INTRODUCTIONThis study investigated the burden of comorbidities and concomitant non-cancer medications and their cost in patients with neuroendocrine tumors (NETs).METHODSAdults with gastroenteropancreatic (GEP)-NETs and lung-NETs, with or without carcinoid syndrome (CS), who initiated first-line NET treatment (index date) with a somatostatin analog or telotristat and had ≥ 1 inpatient or ≥ 2 distinct outpatient claims (study period January 1, 2016-December 31, 2022) were identified from the US MarketScan database and matched (age, sex, insurance type) with up to four adults without cancer (reference group). At 0-90 and 91-180 days post-index, medication counts (generalized linear model, GLM), medication frequency distributions (chi-squared test), and medication costs in USD (two-part model: logit model and GLM for the first and second parts, respectively) were assessed. Frequencies of comorbidities of interest (≥ 1 diagnosis claim) in the 6 months post-index were calculated.RESULTSA total of 662 patients with GEP-NETs (279 with CS) and 84 with lung-NETs (30 with CS) were included. Irrespective of CS status, mean medication counts in the 0-90 and 91-180 days post-index was 1.5-1.8 times higher for GEP-NETs (p < 0.001) and 1.6-1.9 times higher for lung-NETs (p < 0.005) than reference groups. Medications most frequently prescribed for both NET groups were oral cardiovascular, central nervous system, and gastrointestinal agents. The most common comorbidities of interest in patients with NETs (vs reference groups) were hypertension (GEP-NETs: 68.7% vs 55.0%; lung-NETs: 73.8% vs 58.3%) and type 2 diabetes (GEP-NETs: 35.5% vs 24.1%; lung-NETs: 50.0% vs 28.3%). Excluding anticancer medications, mean per-patient-per-month medication costs (vs reference groups) were $276-811 (vs $176-349) and $390-647 (vs $210-$302) for 0-90 days and 91-180 days post-index, respectively.CONCLUSIONCompared with people without cancer, patients with NETs had a higher prevalence of comorbidities and concomitant medication use, which was associated with a greater economic burden.

2025-01-01·Ecotoxicology and Environmental Safety

Inhaling arsenic aggravates airway hyperreactivity by upregulating PNEC-sourced 5-HT in OVA-induced allergic asthma

Article

作者: Yao, Ya-Xin ; Li, Zhao ; Tan, Zhu-Xia ; Lu, Xue ; Li, Ze-Yan ; Xu, De-Xiang ; Wang, Yan ; Zhu, Yan-Yan ; Yang, Qian-Qun ; Peng, Kun

Increasing epidemiological evidence has proved that early-life exposure to inorganic arsenic (As) elevates the risks of childhood asthma. The present research aimed to explore susceptibility of respiratory As exposure to allergic asthma in a mouse model. BALB/c mice on postnatal day (PND) 28 were exposed to ddH₂O or NaAsO₂ aerosol for 4 hours daily over 5 consecutive weeks via respiratory tract. Mice were sensitized by intraperitoneal injection of ovalbumin (OVA) combined with Alum Adjuvant on PND42 and PND56. Subsequently, mice were challenged with ddH₂O or 1 %OVA through a nebulizer for 3 days starting from PND63. In As-exposed mice, OVA-sensitized goblet cell hyperplasia and airway mucosal secretion did not worsen. OVA-induced inflammatory cell infiltration and upregulation of Th2 cytokines, including IL-4, IL-5, and IL-13, were not aggravated in As-exposed mice. Interestingly, airway hyperreactivity was intensified in As-exposed asthmatic mice. Mechanistically, OVA-induced elevation of 5-hydroxytryptamine (5-HT), probably secreted by pulmonary neuroendocrine cells (PNECs), was exacerbated in As-exposed mice. OVA-induced upregulation of tryptophan hydroxylase (TPH)1 and TPH2, two 5-HT synthases, was aggravated in As-exposed mouse lungs. LX1032, a specific TPH inhibitor, suppressed As-induced elevation of pulmonary 5-HT content in asthmatic mice. Moreover, LX1032 alleviated As-evoked airway hyperreactivity in asthmatic mice. These results suggest that respiratory As exposure elevates airway hyperreactivity partially through upregulating PNEC-sourced 5-HT in OVA-induced allergic asthma, which provides significant insight about the hazards of environmental As exposure.

2024-12-01·Molecular Catalysis

Gene hunting and semi-rational design of carbonyl reductase from Kosakonia radicincitans for highly efficient synthesis of the key chiral intermediate of Telotristat ethyl

作者: Liu, Han-Yu ; Wang, Pu ; Zhang, Hai-Min ; Qian, Feng ; Ning, Pan ; Wang, Yao-Wu

Carbonyl reductase exhibits significant potential in the asym. production of chiral alcs. (αR)-4-Chloro-2-(3-methyl-1H-pyrazol-1-yl)-α-(trifluoromethyl)benzenemethanol ((R)-CMPPFO) is a critical precursor for the synthesis of Telotristat Et, an oral drug for the treatment of diarrhea in carcinoid syndrome.Herein, a novel carbonyl reductase KrSDR5 from Kosakonia radicincitans was obtained using gene hunting strategy, capable of asym. reducing the precursor ketone 1-[4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl]-2,2,2-trifluoroethanone (CMPPFA) to (R)-CMPPFO with strict R-stereoselectivity (>99.9% ee).Further, semi-rational design was adopted to acquire a pos. mutant KrSDR5_{T91V/V141M/I159V}, with assistance from a comparative anal. of enzyme-substrate binding mode in mol. dynamics (MD) simulations.This variant displayed a 12.4-fold increase in k_cat/K_m towards CMPPFA compared to the wild-type (WT) KrSDR5.Insights were gained on the high enantioselectivity and the enhancement of enzyme catalytic activity of the mutant through MD simulations.Using the whole-cells of KrSDR5_{T91V/V141M/I159V} as biocatalyst, the asym. synthesis of (R)-CMPPFO was achieved within 20 h at 500 mM CMPPFA concentration, resulting in a 95.0% yield with >99.9% ee, and a highest space-time yield (STY) of 165.7 g·L^-1·d^-1 compared with previous reports.This study provides a robust biocatalyst for highly efficient production of the key precursor (R)-CMPPFO for Telotristat Et, highlighting its potential in the biosynthesis of pharmaceutical intermediates.

项与特罗司他乙酯相关的新闻（医药）

2022-12-07

·PRNewswire

TerSera® to sponsor "NET Cancer Health Storylines" digital platform to support patients suffering from Carcinoid Syndrome Diarrhea

DEERFIELD, Ill., Dec. 7, 2022 /PRNewswire/ -- TerSera Therapeutics announced today a new sponsorship with the Carcinoid Cancer Foundation (CCF) and Alira Health to expand and optimize a holistic patient journey digital platform for patients with Neuroendocrine Tumors and Carcinoid Syndrome. Carcinoid syndrome (CS) is a rare condition that occurs in patients living with metastatic neuroendocrine tumors (mNETs) and is characterized by frequent and debilitating diarrhea that often prevents patients from leading active, predictable lives. Other symptoms of CS include facial flushing, abdominal pain, fatigue and, over time, for some people, heart valve damage.1-3 To support patients in coping with the impact NETs have on their quality of life and collaborate with their care team on treatment decisions, Alira Health and the Carcinoid Cancer Foundation have collaborated since 2015 to build "NET Cancer Health Storylines," a customized version of the Health Storylines™ app that makes it easy for patients to record their symptoms, nutritional concerns, moods, medication and more. The NET Health Storylines app provides patients with resources developed by NET experts. Specific tools include a Stool Diary, NET Nutrition tool, Medication tracker, and additional educational resources. The app is available for download at the NET Cancer Health Storylines website or through the Apple App Store or Google Play. "We are grateful for this support from TerSera to continue to enhance the NET Health Storylines platform to distribute meaningful educational content to NETs patients. The resources available through this platform are important tools in supporting NET patients throughout their journey," said Keith Warner, Chief Executive Officer of the Carcinoid Cancer Foundation. TerSera Therapeutics is the manufacturer of Xermelo (telotristat ethyl), the only oral medication approved for the treatment of carcinoid syndrome diarrhea (CSD), in combination with somatostatin analog (SSA) therapy.4 "Collaborating with CCF and the NET Cancer Health Storylines platform is a fantastic opportunity for us to support patients with Carcinoid Syndrome Diarrhea beyond our existing clinical nurse educator program. We are also looking forward to learning from patients how we can continue to support them better on their journey," said Pamela Gaytan, Executive Director, Clinical Nurse Educators and Patient Advocacy of TerSera Therapeutics. About Carcinoid Syndrome and Carcinoid Syndrome Diarrhea Carcinoid syndrome (CS) is a rare condition which affects approximately 1 out of every 5 patients with neuroendocrine tumors (NETs).5 In CS, patients have NETs that overproduce certain hormones such as serotonin, bradykinin, and histamine.1 One key hormone that is overproduced in CS is serotonin. Elevated serotonin levels in patients with CS can cause carcinoid syndrome diarrhea (CSD) which is characterized by increased motility in the gastrointestinal (GI) tract and reduced absorption of water and nutrients.2 Patients with CSD can experience multiple, urgent, loose and watery stools several times a day. CSD can have a prominent effect on patients' quality of life. Patients with CSD may avoid social activities and have increased fatigue, anxiety, and weight loss.2,3 About Xermelo Xermelo is the first and only approved oral therapy for CSD.4 Xermelo targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within metastatic neuroendocrine tumor (mNET) cells, providing an additional treatment option for patients suffering from CSD. Xermelo is approved in the United States, the European Union, and certain additional countries for the treatment of CSD in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Patients and healthcare professionals with questions about Xermelo should call 1-844-334-4035 or visit . IMPORTANT SAFETY INFORMATION ABOUT XERMELO: Indication Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis. Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops. Adverse Reactions: In a clinical trial of patients with carcinoid syndrome diarrhea and 4-12 bowel movements per day, the most common adverse reactions (≥5%) include nausea, headache, increased gamma-glutamyl transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia. In a second clinical trial of patients with carcinoid syndrome diarrhea and less than 4 bowel movements per day, additional adverse reactions of abdominal pain and constipation were reported in ≥5% of patients. Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 and CYP2B6 substrates, as XERMELO may decrease their systemic exposure. If combination treatment with XERMELO and short-acting octreotide is needed, administer short-acting octreotide at least 30 minutes after administering XERMELO. Use in Special Populations: Xermelo is not recommended in patients with moderate and severe hepatic impairment. For more information, please see the full Prescribing Information for Xermelo. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit , or call 1-800-FDA-1088. You can also contact TerSera Therapeutics at 1-844-334-4035 or [email protected]. About TerSera Therapeutics TerSera Therapeutics acquires, develops, and markets specialty pharmaceutical products with a focus on oncology and non-opioid pain. Its mission is to provide products which truly make a difference for patients. For more information about TerSera Therapeutics, please visit . About Carcinoid Cancer Foundation: The Carcinoid Cancer Foundation is the oldest nonprofit carcinoid and neuroendocrine cancer organization in the United States, founded in 1968. The mission of the foundation is to increase awareness and educate the general public and healthcare professionals regarding neuroendocrine tumors (NETs), to support NET cancer patients and their families, and to serve as patient advocates. Visit the CCF website for more information, . About Alira Health Alira Health is a global healthcare firm whose mission is to humanize healthcare and life sciences in partnership with patients. From development to medical care, we complement the expertise of our Pharma, Biotech, and MedTech clients with a full spectrum of services across their entire solutions lifecycle, including clinical operations, real-world evidence, and patient-centric technology offerings. Our integrated and multidisciplinary team of over 600 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50 MedTech companies and 75% of the top 50 Pharma companies. More information may be obtained at . Media Contacts: References: Clement D, Ramage J, Srirajaskanthan R. Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome. J Oncol. 2020 Jan 21;2020:8341426. Naraev BG, Halland M, Halperin DM, et al. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas. 2019 Sep;48(8):961-972. Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, et al. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. Clin Ther. 2017 Nov;39(11):2158-2168. XERMELO® (telotristat ethyl) Prescribing Information. TerSera Therapeutics LLC. Halperin DM, Shen C, Dasari A, Xu Y, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017 Apr;18(4):525-534. Xermelo® is a registered trademark of TerSera Therapeutics LLC or its affiliates. ©2022 TerSera Therapeutics LLC. All rights reserved. SOURCE TerSera Therapeutics LLC

上市批准

2021-05-06

·GlobeNewswire

Lexicon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical Update

Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 06, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2021 and provided an update on key milestones. “We continue to enroll patients in our two proof-of-concept Phase 2 clinical studies for LX9211 in neuropathic pain and look forward to results from these studies by the end of the year,” said Lonnel Coats, Lexicon’s president and chief executive officer. “We are also very pleased with the regulatory feedback received from the FDA on sotagliflozin in heart failure and we are moving expeditiously forward with a planned NDA filing in that indication this year.” First Quarter Highlights LX9211 Sotagliflozin 2021 Anticipated Milestones and Events First Quarter 2021 Financial Highlights Revenues: Revenues for the three months ended March 31, 2021 were negligible as compared to $8.0 million for the corresponding period in 2020, primarily due to the absence of product revenues as a result of the sale of XERMELO during the third quarter of 2020. Research and Development (R&D) Expenses: Research and development expenses for the three months ended March 31, 2021 decreased to $12.6 million from $55.2 million for the corresponding period in 2020, primarily due to decreases in external clinical development costs related to sotagliflozin resulting from the completion of clinical studies. Selling, General and Administrative (SG&A) Expenses: Selling, general and administrative expenses for the three months ended March 31, 2021 decreased to $8.3 million from $14.7 million for the corresponding period in 2020, primarily due to lower salaries and benefit costs as a result of reductions in personnel in September 2020 and lower marketing expenses. Net Loss: Net loss for the three months ended March 31, 2021 was $21.0 million, or $0.15 per share, as compared to a net loss of $66.6 million, or $0.63 per share, in the corresponding period in 2020. For the three months ended March 31, 2021 and 2020, net income included non-cash, stock-based compensation expense of $2.9 million and $4.4 million, respectively. Cash and Investments: As of March 31, 2021, Lexicon had $141.4 million in cash and investments, as compared to $152.3 million as of December 31, 2020. Conference Call and Webcast Information Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update. The dial-in number for the conference call is 888-645-5785 (U.S./Canada) or 970-300-1531 (international). The conference ID for all callers is 8456671. The live webcast and replay may be accessed by visiting Lexicon’s website at . An archived version of the webcast will be available on the website for 14 days. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit . Safe Harbor Statement This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of LX9211, sotagliflozin and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. Lexicon Pharmaceuticals, Inc. Selected Financial Data For Inquiries: Chas SchultzExecutive Director, Corporate Communications and Investor RelationsLexicon Pharmaceuticals(281) 863-3421cschultz@lexpharma.com

财报

2017-01-31

·BioSpace

6 Biopharma Companies Face Catalysts in February

January 31, 2017 By Mark Terry , BioSpace.com Breaking News Staff If January has been a little bit slow in terms of catalysts in biopharma, February is going to change that. Bret Jensen, writing for Seeking Alpha, discusses a number of PDUFA dates and key clinical trial data releases coming in the month of February. 1. Amgen Amgen ’s Parsabiv has a PDUFA date of February 9. The drug was approved in Europe in November 2016 for the treatment of secondary hyperparathyroidism in adults on hemodialysis. It is up for a decision by the U.S. Food and Drug Administration (FDA) . Amgen is currently trading for $155.74. 2. Valeant Pharmaceuticals The company’s brodalumab for psoriasis is awaiting an FDA decision on February 16. If approved, Valeant Pharmaceuticals would likely launch in the second quarter. The market is projected to be $10 billion. Jensen writes, “The beaten down ‘pariah’ of the drug industry could use any good news at the moment. Valeant is currently trading for $13.60. 3. Amphastar Rancho Cucamonga, Calif.-based Amphastar has a February 19 PDUFA date for an intranasal version of naxolone for opioid overdose. Jensen writes, “I know little of the company but another SeekingAlpha contributor has a bearish view on the company right now. Also after getting burned by the recent FDA labeling decision on the intranasal version of ARYMO ER from Egalet , I would be somewhat leery of the stock and the upcoming FDA decision.” On December 27, 2016, the FDA shot down the company’s New Drug Application for Primatene Mist, indicating that it couldn’t be approved in its present form. Amphastar is currently trading for $15.49. 4. Lexicon Pharmaceuticals Lexicon Pharmaceuticals has a February 28 PDUFA date for Telotristat for carcinoid syndrome. Jensen writes, “Based on trial results, I view the approval as likely and recently highlighted why I like the maker of this compound, Lexicon Pharmaceuticals as an investment right now.” Lexicon is currently trading for $13.93. 5. Amicus Therapeutics Amicus Therapeutics is expected to release additional data from its Phase I/II clinical trial for ATB200 in Pompe Disease at the 13th Annual WORLD Symposium February 13-17. It provided preliminary data in December that was positive. The company is also awaiting a decision in late March in Europe for Galafold for Fabry disease. Jensen writes, “I think Amicus is undervalued just based on its approved compound Galafold for the treatment of Fabry Disease outside the United States.” Amicus is currently trading for $5.33. 6. Axovant Sciences Axovant Sciences is expected to announce Phase II data from its trial of Nelotanserin for visual hallucinations associated with Lewy body dementia. In early December, Axovant announced positive data from a Phase IIb trial of intepirdine (RVT-101), combined with standard of care donepezil, in mild-to-moderate Alzheimer’s disease. Jensen writes, “It is a busy year for the company’s pipeline development. The key catalyst will be for Phase III data for its compound Intepirdine aimed at Alzheimer’s Disease. This is due out in the third quarter and most likely to cause at least a 50 percent move in either direction when released depending on the results.” Axovant is currently trading for $11.98.

临床结果上市批准临床2期临床3期

100 项与特罗司他乙酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09974 D09975	特罗司他乙酯	A16A	DB12095

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
恶性类癌综合征	美国	TerSera Therapeutics LLC	2017-02-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
恶性类癌综合征	药物发现	加拿大	Lexicon Pharmaceuticals, Inc.	2013-01-08
恶性类癌综合征	药物发现	意大利	Lexicon Pharmaceuticals, Inc.	2013-01-08
恶性类癌综合征	药物发现	美国	Lexicon Pharmaceuticals, Inc.	2013-01-08
恶性类癌综合征	药物发现	英国	Lexicon Pharmaceuticals, Inc.	2013-01-08
恶性类癌综合征	药物发现	比利时	Lexicon Pharmaceuticals, Inc.	2013-01-08
恶性类癌综合征	药物发现	澳大利亚	Lexicon Pharmaceuticals, Inc.	2013-01-08
恶性类癌综合征	药物发现	瑞典	Lexicon Pharmaceuticals, Inc.	2013-01-08
恶性类癌综合征	药物发现	以色列	Lexicon Pharmaceuticals, Inc.	2013-01-08
恶性类癌综合征	药物发现	西班牙	Lexicon Pharmaceuticals, Inc.	2013-01-08
恶性类癌综合征	药物发现	德国	Lexicon Pharmaceuticals, Inc.	2013-01-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03453489 (CTgov)	临床2期	恶性类癌综合征	4	Positron Emission Tomography+Telotristat Etiprate	鏇鬱鹽膚鹽窪繭窪衊窪(築鹹鏇願艱選鹹憲艱鏇) = 願襯網膚鑰築夢衊選艱壓衊構網襯鏇築艱壓鏇 (窪夢鏇鑰積積醖艱網繭, 餘繭網鬱鬱憲觸窪網餘 ~ 鑰夢製淵鑰顧淵憲鹽艱) 更多	-	2025-04-10
NCT04543955 (CTgov)	临床2期	神经内分泌肿瘤	1	Telotristat (Low-Dose) (Arm 1: Low-Dose Telotristat)	網積繭衊壓觸夢鹽積顧(觸築襯壓鬱艱淵製築觸) = 顧網蓋淵廠築蓋憲廠觸構觸餘淵鹽衊鑰觸鹹鏇 (夢積廠遞膚獵蓋糧網築, 願膚鏇衊製餘夢衊鏇顧 ~ 觸鬱繭鏇糧選製齋範艱) 更多	-	2023-06-27
				Telotristat (High-Dose) (Arm 2: High-Dose Telotristat)	網積繭衊壓觸夢鹽積顧(觸築襯壓鬱艱淵製築觸) = 鬱衊簾齋範遞憲選遞衊構觸餘淵鹽衊鑰觸鹹鏇 (夢積廠遞膚獵蓋糧網築, 壓襯夢製醖網選選積選 ~ 觸廠簾蓋鬱膚簾顧夢餘) 更多
NCT03790111 (TELE-ABC, CTgov)	临床2期	晚期胆管癌	53	Xermelo	壓選糧鬱鏇鏇廠選顧觸(廠鏇選選鏇衊蓋壓簾鏇) = 憲窪壓製觸選窪積觸鬱餘鬱觸蓋襯獵廠鏇糧餘 (積糧觸範觸構糧襯簾鏇, 觸糧觸遞餘窪蓋構願築 ~ 鏇襯憲鑰遞製選獵選憲) 更多	-	2023-04-19
NCT01677910 \| NCT02063659 (TELECAST, Pubmed \| Clin Ther)	临床3期	恶性类癌综合征	-	Telotristat Ethyl	構廠齋衊淵築獵網構範(鏇範壓製襯衊蓋繭鹽膚) = 觸夢遞齋構壓選鑰鬱窪構鹹鹽繭淵窪餘壓範淵 (餘壓網願鏇廠製範範衊 ) 更多	-	2021-10-01
TELEACE (ASCO_GI2021)	N/A	高分化胰腺内分泌肿瘤	-	Telotristat ethyl	餘夢醖鏇艱顧遞簾鏇糧(淵淵壓鏇構衊憲夢壓鏇) = 願積廠壓醖壓鹹範廠網鹽觸醖衊餘鬱顧襯製製 (築選繭範築範觸夢夢觸 )	积极	2021-01-22
NCT02026063 (TELEPATH, CTgov)	临床3期	恶性类癌综合征	124	Telotristat Etiprate (Telotristat Etiprate 250 mg)	獵窪窪顧積夢繭鑰鹹衊(廠醖壓願齋壓選觸繭醖) = 鑰醖蓋艱遞積構獵願網廠遞鹹糧壓繭繭鏇鏇憲 (鹽襯淵遞糧餘鏇艱淵醖, 蓋鬱觸選遞築繭膚築鹽 ~ 蓋鹽糧艱構夢鑰獵齋艱) 更多	-	2019-09-17
				Etiprate+Telotristat (Telotristat Etiprate 500 mg)	獵窪窪顧積夢繭鑰鹹衊(廠醖壓願齋壓選觸繭醖) = 廠餘襯範醖醖齋繭醖鏇廠遞鹹糧壓繭繭鏇鏇憲 (鹽襯淵遞糧餘鏇艱淵醖, 夢憲衊鹽鑰窪顧願鹽淵 ~ 憲憲網衊鏇壓鹹糧鬱衊) 更多
NCT03442725 (CTgov)	临床1期	肾功能不全	16	telotristat etiprate (Healthy Subjects (Control Group))	蓋鏇憲廠淵夢繭鑰窪繭(襯選壓襯壓鏇膚範襯憲) = 壓膚憲鹽襯鏇窪齋齋餘遞獵艱餘鏇蓋艱憲艱膚 (廠襯醖壓獵築襯夢獵憲, 鹽鏇網膚獵鏇鏇廠繭餘 ~ 糧觸簾艱繭鬱遞範膚獵) 更多	-	2019-09-13
				telotristat etiprate (Severe Renal Impairment (Test Group))	蓋鏇憲廠淵夢繭鑰窪繭(襯選壓襯壓鏇膚範襯憲) = 淵糧選遞餘網夢齋壓積遞獵艱餘鏇蓋艱憲艱膚 (廠襯醖壓獵築襯夢獵憲, 鬱遞襯遞淵糧獵鑰齋艱 ~ 鬱鏇壓襯選餘獵網積醖) 更多
NCT00853047 (CTgov)	临床2期	恶性类癌综合征	23	Placebo+Octreotide LAR Depot (Placebo Core Phase)	鏇蓋鏇膚構襯窪齋獵鏇(遞艱淵糧構淵艱醖選鬱) = 醖齋簾衊繭艱觸製築鹹憲鏇積壓蓋鏇鬱夢淵餘 (醖膚簾簾淵鏇齋鏇鹹願, 夢窪顧齋顧壓鹽壓襯襯 ~ 鹽廠鑰餘襯遞壓憲憲願) 更多	-	2018-12-26
				Octreotide LAR Depot+Telotristat etiprate (Telotristat Etiprate 150 mg Core Phase)	鏇蓋鏇膚構襯窪齋獵鏇(遞艱淵糧構淵艱醖選鬱) = 襯獵膚築鏇蓋蓋膚衊簾憲鏇積壓蓋鏇鬱夢淵餘 (醖膚簾簾淵鏇齋鏇鹹願, 觸艱願簾構壓鏇廠憲鑰 ~ 繭憲築選獵鹹觸淵糧繭) 更多
NCT01677910 (TELESTAR, Pubmed \| Clin Ther)	临床3期	恶性类癌综合征	135	Placebo	(衊憲網壓夢夢製淵淵鬱) = 衊壓蓋蓋簾餘製鏇鏇鏇觸艱醖鏇構鏇積遞夢構 (遞鹽願觸蓋簾製鑰鑰鬱 ) 更多	-	2018-06-01
				Telotristat ethyl 250 mg	(衊憲網壓夢夢製淵淵鬱) = 淵憲窪網範壓繭餘齋壓觸艱醖鏇構鏇積遞夢構 (遞鹽願觸蓋簾製鑰鑰鬱 ) 更多
NCT01104415 (CTgov)	临床2期	恶性类癌综合征	15	Telotristat (Telotristat Etiprate- Core Phase)	構範衊鏇餘繭積顧範憲(膚鏇簾夢選醖艱窪積壓) = 網鏇築餘齋夢簾蓋鏇構網餘繭鑰齋選襯願廠積 (繭觸膚窪願築窪餘醖齋, 網淵膚構餘鹹窪獵繭膚 ~ 製鑰餘選顧膚構膚範觸) 更多	-	2018-04-06
				Telotristat (Telotristat Etiprate- Extension Period)	觸醖網鬱蓋糧鑰範艱糧(鑰齋糧襯淵遞網積餘艱) = 選獵蓋選憲獵製憲選鑰鹽齋網鬱構製獵夢醖觸 (繭廠壓製窪夢鑰襯網顧, 齋顧鏇範願遞艱願鏇蓋 ~ 衊構遞壓糧鬱鬱鑰齋蓋) 更多